Hostname: page-component-848d4c4894-hfldf Total loading time: 0 Render date: 2024-06-01T03:02:35.007Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical Experiences and Clinical Trials

Published online by Cambridge University Press:  07 November 2014

Robert Rosenheck
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Communique
Information
CNS Spectrums , Volume 13 , Issue 6 , June 2008 , pp. 461 - 463
Copyright
Copyright © Cambridge University Press 2008

References

REFERENCES

1.Marder, SR. Newer antipsychotics and the difference between clinical experiences and clinical trials. CNS Spectr. 2007;12:812–815.Google ScholarPubMed
2.Lieberman, JA, Stroup, TS, McEvoy, JP, et al, for the CATIE Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. N Eng J Med. 2005;353:1209–1223.CrossRefGoogle Scholar
3.Rosenheck, RA, Leslie, D, Sindelar, J, et al.Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163:2080–2089.Google Scholar
4.Keefe, RSE, Bilder, RM, Davis, SM, et al; CATIE Investigators; Neurocognitive Working Group. Neurocognitive effect of antipsychotic medications in patients with chronic schizophrenia in the CATIE study. Arch Gen Psychiatry. 2007;64:633–647.Google Scholar
5.Swartz, M, Perkins, D, Stroup, S, et al; CATIE Investigators. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: Findings from the NIMH CATIE Study. Am J Psychiatry. 2007;164:428–436.CrossRefGoogle ScholarPubMed
6.Resnick, SG, Rosenheck, RA, Stroup, TS, et al for the CATIE Study Investigators. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. J Behav Health Serv Res. 2008; In press.Google Scholar
7.Swanson, JW, Swartz, MS, Van Dorn, RA, et al for the CATIE Investigators. Effectiveness of antipsychotic drugs for reducing violence in persons with chronic schizophrenia: Findings from the NIMH CATIE Study. Br J Psychiatry. 2008; In press.Google Scholar
8.Rosenheck, RA, Stroup, TS, Keefe, RSE, McEvoy, J, Swartz, M, Lieberman, JA. Study samples key to assessing risk [letter]. Current Psychiatry. 2007;6:3–4.Google Scholar
9.Tollefson, GD, Beasley, CM Jr, Tran, PV, et al.Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457–465.Google Scholar
10.Marder, SR, Meibach, RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825–835.Google Scholar
11.Hogan, TP, Awad, AG, Eastwood, R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177–183.Google Scholar
12.Correll, CU, Leucht, S, Kane, JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414–425.Google Scholar
13.Halliday, J, Farrington, S, Macdonald, S, MacEwan, T, Sharkey, V, McCreadie, R. Nithsdale Schizophrenia Surveys 23: movement disorders 20-year review. Br J Psychiatry. 2002;181:422–427.Google Scholar
14.Lee, PE, Sykora, K, Gill, SS, et al.Antipsychotic medication and drug-induced movement disorder: a population-based cohort study in older adults. J Am Geriatr Soc. 2005;53:1374–1379.Google Scholar
15.Rochon, PA, Stukel, TA, Sykora, K, et al.Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005;165:1882–1888.Google Scholar
16.Bausell, RB. Snake Oil Science: The Truth About Complementary and Alternative Medicine. New York, NY: Oxford University Press; 2007.Google Scholar
17.Ariely, D. The power of price: why a 50-cent aspirin can do what a penny aspirin can't. In: Predictably Irrational: The Hidden Forces That Shape Our Decisions. New York, NY: HarperCollins; 2008;173–194.Google Scholar